Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830-0011, Japan.
J Cardiol. 2011 May;57(3):257-62. doi: 10.1016/j.jjcc.2011.01.011. Epub 2011 Mar 2.
Diabetes is associated with a marked increased risk of atherosclerotic vascular disorders, including coronary, cerebrovascular, and peripheral artery disease. Cardiovascular disease (CVD) could account for disabilities and high mortality rates in patients with diabetes. Conventional risk factors, including hyperlipidemia, hypertension, smoking, obesity, lack of exercise, and a positive family history, contribute similarly to macrovascular complications in type 2 diabetic patients and non-diabetic subjects. The levels of these factors in diabetic patients are certainly increased, but not enough to explain the exaggerated risk for macrovascular complications in the diabetic population. Furthermore, recently, macrovascular complications of diabetes have been shown to start before the onset of diabetes. Indeed, several clinical studies have confirmed the increased risk of CVD in patients with impaired glucose tolerance (IGT). Since insulin resistance-related postprandial metabolic derangements are thought to play a central role in the development and progression of CVD in patients with IGT, amelioration of postprandial metabolic disturbance is a therapeutic target for the prevention of CVD in these high-risk patients. Therefore, in this paper, we review the molecular mechanisms for the increased risk of CVD in recent onset diabetes mellitus, especially focusing on postprandial dysmetabolism. We also discuss here the potential therapeutic strategies that specially target the mechanisms responsible for vascular alterations in diabetes.
糖尿病与动脉粥样硬化性血管疾病的风险显著增加有关,包括冠心病、脑血管病和外周动脉疾病。心血管疾病(CVD)可能导致糖尿病患者残疾和高死亡率。传统的危险因素,包括高脂血症、高血压、吸烟、肥胖、缺乏运动和阳性家族史,同样会导致 2 型糖尿病患者和非糖尿病患者的大血管并发症。这些因素在糖尿病患者中的水平肯定会升高,但不足以解释糖尿病患者大血管并发症的风险增加。此外,最近,糖尿病的大血管并发症已被证明在糖尿病发病前就开始了。事实上,几项临床研究证实,糖耐量受损(IGT)患者的 CVD 风险增加。由于胰岛素抵抗相关的餐后代谢紊乱被认为在 IGT 患者 CVD 的发生和发展中起核心作用,因此改善餐后代谢紊乱是预防这些高危患者 CVD 的治疗靶点。因此,本文综述了新发糖尿病患者 CVD 风险增加的分子机制,特别是关注餐后代谢异常。我们还在这里讨论了专门针对糖尿病血管改变相关机制的潜在治疗策略。